![conference banner](/images/conference-banner.jpeg)
Abstract
Patients with well-differentiated neuroendocrine tumours of the gastrointestinal tract often present with metastases and hormonal symptoms. These patients can be palliated by interventional tumour reduction and medical treatment with somatostatin analogues; no effective chemotherapy is available. Radionuclide therapy via somatostatin receptors is one new therapeutic alternative. The recognition that neuroendocrine tumours express specific receptors for growth factors and chemokines, which are of importance for tumour growth, vascularization, and spread, may open the way for new therapeutic approaches. The signalling pathways in carcinoid tumours are incompletely explored. This review summarizes potential new treatment strategies from clinical and experimental studies, e.g. inhibition of angiogenesis, targeting of growth factors or their receptors by tyrosine kinase inhibitors, interference with specific cellular pathways (mTOR, PI3K, RAS/RAF, Notch), and also inhibition of the proteasome and histone deacetylation. Combining targeted therapy with chemotherapy, or using drugs to sensitize for radionuclide therapy, may enhance the treatment outcome.
Keywords: monoclonal antibody, growth factor receptor, Angiogenesis inhibition, multikinase inhibition, neuroendocrine tumour, radionuclide therapy, small molecule inhibitor, somatostatin receptor
Anti-Cancer Agents in Medicinal Chemistry
Title: New Medical Strategies for Midgut Carcinoids
Volume: 10 Issue: 3
Author(s): Ola Nilsson, Yvonne Arvidsson, Viktor Johanson, Eva Forssell-Aronsson and Hakan Ahlman
Affiliation:
Keywords: monoclonal antibody, growth factor receptor, Angiogenesis inhibition, multikinase inhibition, neuroendocrine tumour, radionuclide therapy, small molecule inhibitor, somatostatin receptor
Abstract: Patients with well-differentiated neuroendocrine tumours of the gastrointestinal tract often present with metastases and hormonal symptoms. These patients can be palliated by interventional tumour reduction and medical treatment with somatostatin analogues; no effective chemotherapy is available. Radionuclide therapy via somatostatin receptors is one new therapeutic alternative. The recognition that neuroendocrine tumours express specific receptors for growth factors and chemokines, which are of importance for tumour growth, vascularization, and spread, may open the way for new therapeutic approaches. The signalling pathways in carcinoid tumours are incompletely explored. This review summarizes potential new treatment strategies from clinical and experimental studies, e.g. inhibition of angiogenesis, targeting of growth factors or their receptors by tyrosine kinase inhibitors, interference with specific cellular pathways (mTOR, PI3K, RAS/RAF, Notch), and also inhibition of the proteasome and histone deacetylation. Combining targeted therapy with chemotherapy, or using drugs to sensitize for radionuclide therapy, may enhance the treatment outcome.
Export Options
About this article
Cite this article as:
Nilsson Ola, Arvidsson Yvonne, Johanson Viktor, Forssell-Aronsson Eva and Ahlman Hakan, New Medical Strategies for Midgut Carcinoids, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (3) . https://dx.doi.org/10.2174/1871520611009030250
DOI https://dx.doi.org/10.2174/1871520611009030250 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Rechallenge Therapy in different types of cancer
Cancer is responsible for approximately 8 million deaths annually worldwide. GLOBOCAN 2020 reported 19.3 million new cases of cancer, which is projected to increase to 28.4 million by 2040. In the future, female breast cancer will be the most common cancer (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Molecular and Metabolic Imaging of Hepatic Neuroendocrine Tumors Following Radioembolization with 90Y-microspheres
Current Medical Imaging Somatostatin and its Analogs
Current Drug Targets The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Thematic Analysis™ : A Chemogenomic Approach to GPCR Drug Discovery
Current Topics in Medicinal Chemistry Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy The Psychiatric Drug Lithium Increases DNA Damage and Decreases Cell Survival in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines Expos ed to Ionizing Radiation
Current Molecular Pharmacology Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Novel Subtype Specific and Universal Somatostatin Analogues: Clinical Potential and Pitfalls
Current Pharmaceutical Design Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry Structure-Activity Relationships of Histamine H2 Receptor Ligands+
Mini-Reviews in Medicinal Chemistry The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)
Current Radiopharmaceuticals Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets